Loading...

ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers

Published
13 Apr 25
Updated
01 May 25
AnalystConsensusTarget's Fair Value
€10.56
57.2% undervalued intrinsic discount
01 May
€4.52
Loading
1Y
83.0%
7D
1.6%

Author's Valuation

€10.6

57.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 0.095%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on24 Apr 25
Fair value Increased 0.095%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.